Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 16, 2026Cardiorenal MedicineOpen Access

Potential mechanisms of sodium-glucose cotransporter 2 inhibitors in regulating cardiac and renal fibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

WHWei HuangUniversity of Nottingham Ningbo ChinaTGTianxiang GuanGuangzhou University of Chinese MedicineZYZiyou YanAffiliated Hospital of Jiangxi University of Traditional Chinese Medicine

Discussion

Loading...

Member takes

Implication

Review explores mechanisms by which SGLT2 inhibitors regulate fibrosis in cardiac and renal contexts, suggesting implications for disease management.

Key Points

  • This review aims to elucidate the mechanisms through which SGLT2 inhibitors influence cardiac and renal fibrosis.
  • Comprehensive analysis of existing literature on SGLT2 inhibitors and their effects in CKD and T2DM.
  • Focus on molecular and cellular pathways involved in cardiac and renal fibrosis.
  • Discussion of hypoglycemic effects and cardiovascular risk reduction.
  • SGLT2 inhibitors slow CKD progression and lower cardiovascular risk.
  • These agents are associated with modulation of cardiac and renal fibrosis.
  • Detailed molecular pathways remain largely unexplained.

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/6a0809d7a487c87a6a40bad7https://doi.org/10.1159/000551330
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench2020 · 42 citations
  2. 2Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis2017 · 946 citations
  3. 3SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms2024 · 11 citations
  4. 4Comparative Study of the Effects of GLP1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms2020 · 53 citations
  5. 5Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling2022 · 67 citations